News blog
Futura Medical
- BY: Andrew Hore |
- POSTED: 16/12/2009 |
Futura Medical is negotiating a licence agreement for its TPR100 topical pain relief with a major pharma company.
The potential licensee paid an initial fee to evaluate the product and has paid a further £50,000 while negotiations continue.
Futura hopes the negotiations will be concluded in the first half of 2010. It is unclear what territories any licence would cover.
Futura says tests show that TPR100 achieves between 30 to 40 times higher bioavailability than the current market-leading product. This makes it work faster.
Discussions with potential partners for the PET500 treatment for enhanced sexual control are underway.
At 32.25p a share, up 4p on the day, Futura is valued at £21.8m.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|